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Recent work has shown that cytotoxic T cells play a central role in immune-mediated control of 
cancers1-3, and monoclonal antibodies that target inhibitory receptors on T cells can induce 
significant clinical benefit in patients despite advanced disease4-6.  However, many of the 
regulatory pathways that result in loss of T cell function within immunosuppressive tumors 
remain unknown.  Here we show that such regulatory mechanisms can be systematically 
discovered in vivo in the tumor microenvironment.  We devised a pool shRNA screening approach 
aimed at identifying genes that block the function of tumor-infiltrating CD8 T cells.  We 
postulated that shRNAs targeting key inhibitors would enable robust T cell infiltration and 
proliferation in tumors, despite multiple inhibitory signals.  Candidate shRNAs were discovered 
by transfer of shRNA-transduced T cells into tumor-bearing mice, followed by deep sequencing to 
quantify the representation of all hairpins in tumors and lymphoid organs.  A subset of shRNAs 
induced T cell accumulation in tumors but not the spleen, demonstrating feasibility of discovering 
shRNAs with differential action across tissues.  One of the targets was Ppp2r2d, a regulatory 
subunit of the family of PP2A phosphatases7. Control shRNA-transduced T cells underwent 
apoptosis upon recognition of melanoma cells, while Ppp2r2d shRNA-transduced T cells 
accumulated in tumors due to enhanced proliferation and reduced apoptosis.  Ppp2r2d shRNA-
expressing T cells also significantly delayed tumor growth.  This in vivo approach has wide 
applications to dissect complex immune functions in relevant tissue microenvironments.   
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Immune cells perform complex surveillance functions throughout the body and interact with many 
different types of cells in distinct tissue microenvironments.  Therapeutic targets for modulating immune 
responses are typically identified in vitro and tested in animal models at a late stage of the process.  We 
postulate that the complex interactions of immune cells within tissues - many of which do not occur in 
vitro - offer untapped opportunities for therapeutic intervention.  Here we have addressed the challenge 
of how targets for immune modulation can be systematically discovered in vivo.  This is a central issue 
in oncology because strong infiltration by CD8 T cells - which have cytotoxic function against tumor 
cells - is associated with a favorable prognosis in multiple types of human cancer1,3,8.  Unfortunately, 
this natural defense mechanism is severely blunted in the majority of patients by multiple inhibitory 
signals emanating from the tumor, its stroma, regulatory T cells and myeloid cell populations.9-11  
Pooled shRNA libraries have been shown to be powerful discovery tools12,13.  We reasoned that shRNAs 
capable of restoring CD8 T cell function can be systematically discovered in vivo by taking advantage of 
the extensive proliferative capacity of T cells following triggering of the T cell receptor by a tumor-
associated antigen.  When introduced into T cells, only a small subset of shRNAs from a pool will 
restore T cell proliferation resulting in their enrichment within tumors.  Over-representation of active 
shRNAs within each pool can be quantified by deep sequencing of the shRNA cassette from tumors and 
secondary lymphoid organs (Fig. 1a). 
We chose B16 melanoma, an aggressive tumor that is difficult to treat14.  Melanoma cells expressed the 
surrogate tumor antigen Ovalbumin (Ova), which is recognized by CD8 T cells from OT-I T cell 
receptor transgenic mice15,16.  Initial experiments showed that such a screen could also be performed 
with pmel-1 T cells that recognize gp100, an endogenous melanoma antigen17, but the signal/noise ratio 
was lower for pmel-1 T cells due to smaller T cell populations in tumors.  Naïve T cells are difficult to 
infect with lentiviral vectors, and we therefore pretreated T cells for two days with the homeostatic 
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cytokines IL-7 and IL-15 prior to spin infection with shRNA pools in a lentiviral vector.  Successful 
transduction was monitored by surface expression of the Thy1.1 reporter (Fig. S1a).  T cells were 
injected into B6 mice bearing day 14 B16-Ova tumors.  Seven days later, T cells were purified from 
tumors and secondary lymphoid organs (spleen, tumor-draining and irrelevant lymph nodes) for 
isolation of genomic DNA, followed by PCR amplification of the shRNA cassette (Fig. S1b).  The 
representation of shRNAs was then quantified in different tissues by Illumina sequencing.   
Two large screens were performed, with the first focusing on genes over-expressed in dysfunctional T 
cells (T cell anergy or exhaustion; 255 genes, 1,275 shRNAs divided into two pools), and the second on 
kinases/phosphatases (1,307 genes, 6,535 shRNAs divided into seven pools) (Fig. 1b).  In these primary 
screens, each gene was represented by ~5 shRNAs (it is common that only one or two of such shRNAs 
have sufficient activity in pooled screens).  We observed multiple distinct in vivo phenotypes.  For 
certain genes, shRNAs were over-represented in all tested tissues compared to the starting T cell 
population (e.g. SHP-1), indicative of enhanced proliferation independent of T cell receptor recognition 
of a tumor antigen.  For other genes, there was a selective loss of shRNAs within tumors (e.g. ZAP-70, a 
critical kinase in the T cell activation pathway).  We focused our analysis on genes whose shRNAs 
showed substantial over-representation in tumor but not spleen, a secondary lymphoid organ.  
Substantial T cell accumulation in tumors was observed for a number of shRNAs, despite the 
immunosuppressive environment.  For secondary screens, we created focused pools in which each 
candidate gene was represented by ~15 shRNAs.  Primary data from this analysis are shown for three 
genes in Fig. 1c: LacZ (negative control), Cblb (an E3 ubiquitin ligase that induces T cell receptor 
internalization)18 and Ppp2r2d (not previously studied in T cells).  For both Ppp2r2d and Cblb, five 
shRNAs were substantially increased in tumors (red) compared to spleen, while no enrichment was 
observed for LacZ shRNAs.  Overall, 43 genes met the following criteria: ≥4-fold enrichment for 3 or 
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more shRNAs in tumors compared to spleen (Fig. 1b, Fig. S1c,d).  The set included gene products 
previously identified as inhibitors of T cell receptor signaling (including Cblb, Dgka, Dgkz, Ptpn2) as 
well as other well-known inhibitors of T cell function (e.g. Smad2, Socs1, Socs3, Egr2), validating our 
approach (Fig. 1d, Fig. S2).19-21 
We next confirmed at a cellular level that these shRNAs induce T cell accumulation in tumors.  T cells 
were infected with lentiviral vectors driving expression of a single shRNA and a reporter protein 
(Thy1.1 or one of four different fluorescent proteins), and after seven days the frequency of shRNA-
transduced T cells was quantified in tumors, spleens and lymph nodes by flow cytometry.  When the 
control LacZ shRNA was expressed in CD8 T cells, the frequency of shRNA-expressing CD8 T cells 
was lower in tumors compared to spleen (~2-fold).  In contrast, experimental shRNAs induced 
accumulation of CD8 T cells in tumors but not the spleen (Fig. 2a, Fig. S3).  For seven of these genes, T 
cell accumulation in tumors was >10-fold relative to spleen.  The strongest phenotype was observed 
with shRNAs targeting Ppp2r2d, a regulatory subunit of the family of PP2A phosphatases7.  A Ppp2r2d 
shRNA not only induced accumulation of OT-I CD8 T cells, but also CD4 T cells (from TRP-1 TCR 
transgenic mice)22, with T cell numbers in tumors being significantly higher when Ppp2r2d rather than 
LacZ shRNA was expressed (36.3-fold for CD8; 16.2-fold for  CD4 T cells) (Fig. 2b).  CD8 T cell 
accumulation correlated with the degree of Ppp2r2d knock-down, and two Ppp2r2d shRNAs with the 
highest in vivo activity induced the lowest levels of Ppp2r2d mRNA (Fig. S3b).  Ppp2r2d knockdown 
was also confirmed at the protein level using a quantitative mass spectrometry approach (Fig. S3c).  
Ppp2r2d shRNA activity was specific because the phenotype was reversed when a Ppp2r2d cDNA (with 
wild-type protein sequence, but mutated DNA sequence at the shRNA binding site) was co-introduced 
with the Ppp2r2d shRNA (Fig. 2c, Fig. S4).  Furthermore, OT-I CD8 T cells over-expressed Ppp2r2d in 
tumors compared to spleen (in the absence of any shRNA expression), suggesting that it is an intrinsic 
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component of the signaling network inhibiting T cell function in tumors (Fig. 2d).  Microarray analysis 
of tumor-infiltrating T cells expressing different shRNAs showed that each shRNA induced a largely 
distinct set of gene expression changes, indicating that improved T cell function in tumors can be 
mediated through a number of different intracellular pathways (Fig. S5).   
We next examined the cellular mechanisms driving T cell accumulation by a Ppp2r2d shRNA in tumors 
- specifically T cell infiltration, proliferation and apoptosis.  T cell infiltration into tumors was assessed 
by transfer of OT-I CD8 T cells labeled with a cytosolic dye, CFSE.  No differences were observed in 
the frequency of Ppp2r2d or LacZ shRNA-transduced CD8 T cells in tumors on day 1, arguing against a 
substantial effect on T cell infiltration (Fig. 3a).  However, analysis of later time points (days 3-7) 
demonstrated a higher degree of proliferation (based on CFSE dilution) by Ppp2r2d compared to LacZ 
shRNA-transduced T cells (Fig. 3b, Fig. S6a).  Substantial T cell proliferation was even observed for 
LacZ shRNA-transduced T cells (complete dilution of CFSE dye by day 7), despite the presence of 
small numbers of such cells in tumors.  This suggested that LacZ shRNA-transduced T cells were lost by 
apoptosis.  Indeed, a larger percentage of tumor-infiltrating T cells were labeled with an antibody 
specific for active caspase-3 when the LacZ control shRNA (rather than Ppp2r2d shRNA) was expressed 
(Fig. 3c, Fig. S6b).  Furthermore, co-culture of CD8 T cells with B16-Ova tumor cells showed that the 
majority of LacZ shRNA expressing T cells became apoptotic (65.7%) while the majority of Ppp2r2d 
shRNA-transduced T cells were viable (89.5%, Fig. S6c).  Ex vivo analysis of tumor-infiltrating T cells 
at a single-cell level with a nanowell device also demonstrated increased cytokine production by T cells 
expressing Ppp2r2d compared to LacZ shRNA (Fig. S7b, c).  In addition, intracellular cytokine staining 
confirmed production of higher levels of interferon-γ (IFNγ), a cytokine critical for anti-tumor immunity 
(Fig. 3d, S7a).  The action of Ppp2r2d was downstream of T cell receptor activation because T cell 
proliferation was enhanced in tumors and to a lesser extent in tumor-draining lymph nodes (Fig. S6).  In 
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contrast, no proliferation was observed in irrelevant lymph nodes or the spleen where the relevant 
antigen is not presented to T cells (data not shown).  
These results suggested the possibility that Ppp2r2d shRNA-transduced CD8 T cells may be able to 
proliferate and survive even when they recognize their antigen directly presented by B16-Ova tumor 
cells.  This idea was tested by implantation of tumor cells into b2m-/- mice which are deficient in 
expression of MHC class I proteins23.  In such mice, only tumor cells but not professional antigen 
presenting cells of the host could present tumor antigens to T cells.  Indeed, Ppp2r2d shRNA-transduced 
OT-I CD8 T cells showed massive accumulation within B16-Ova tumors in b2m-/- mice (Fig. 3e) while 
there were very small numbers of T cells in contralateral B16 tumors that lacked expression of the Ova 
antigen.  T cells expressing a Ppp2r2d shRNA could thus effectively proliferate and survive in response 
to tumor cells, despite a lack of suitable co-stimulatory signals and an inhibitory microenvironment.   
PP2A represents a family of phosphatase complexes composed of catalytic, scaffolding and regulatory 
subunits.  Cellular localization and substrate specificity are determined by one of many regulatory 
subunits of which Ppp2r2d is a member7.  Ppp2r2d directs PP2A to Cdk1 substrates during interphase 
and anaphase; it thereby inhibits entry into mitosis and induces exit from mitosis24.  PP2A also plays a 
gatekeeper role for BAD-mediated apoptosis.  Phosphorylated BAD is sequestered in its inactive form in 
the cytosol by 14-3-3, while dephosphorylated BAD is targeted to mitochondria where it causes cell 
death by binding Bcl-XL and Bcl-225.  PP2A phosphatases have also been shown to interact with the 
cytoplasmic domains of CD28 and CTLA-4 as well as Carma1 (upstream of the NF-B pathway)26,27, 
but it is not known which regulatory subunits are required for these activities; Ppp2r2d antibodies 
suitable for the required biochemical studies are currently not available.        
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Finally, we assessed the ability of a Ppp2r2d shRNA to enhance the efficacy of adoptive T cell therapy.  
B16-Ova tumor cells (2x105) were injected subcutaneously into B6 mice.  On day 12, mice bearing 
tumors of similar size were divided into seven groups, either receiving no T cells, 2x106 shRNA-
transduced TRP-1 CD4 T cells, 2x106 shRNA infected OT-I CD8 T cells, or both CD4 and CD8 T cells 
(days 12 and day 17).  The modest anti-tumor activity of OT-I CD8 T cells (expressing the control LacZ 
shRNA) is consistent with published data28.  Ppp2r2d shRNA improved the therapeutic activity of both 
CD4 and CD8 T cells (Fig. 4a,b).  A Ppp2r2d shRNA also enhanced anti-tumor responses when 
introduced into T cells specific for the endogenous melanoma antigens gp100 (pmel-1 CD8 T cells) and 
TRP-1 (TRP-1 CD4 T cells) (Fig. 4c).  Gp100 is a relevant antigen in human melanoma, and a clinical 
trial in which a gp100-specific TCR (isolated from HLA-A2 transgenic mice) was introduced into 
peripheral blood T cells demonstrated therapeutic benefit in a subset of patients 29.   
T cells expressing Ppp2r2d shRNAs acquired an effector phenotype in tumors (Fig. S8a) and >30% of 
the cells expressed granzyme B (Fig. S8c).  Consistent with greatly increased numbers of such effector T 
cells in tumors (Fig. S9a), TUNEL staining demonstrated increased apoptosis in tumors when Ppp2r2d 
rather than LacZ shRNA expressing T cells were present (Fig. S9b).  B16 melanomas are highly 
aggressive tumors in part because MHC class I expression is very low.  Interestingly, Ppp2r2d but not 
LacZ shRNA-expressing T cells significantly increased MHC class I expression (H-2Kb) by tumor cells, 
possibly due to the observed increase in IFNγ secretion by T cells (Fig. S9c, Fig. S7).  A Ppp2r2d 
shRNA did not reduce expression of inhibitory PD-1 or LAG-3 receptors on tumor-infiltrating T cells, 
demonstrating that its mechanism of action is distinct from these known negative regulators of T cell 
function (Fig. S8b).  This finding suggests combination approaches targeting these intracellular and cell 
surface molecules.      
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These results establish the feasibility of in vivo discovery of novel targets for immunotherapy in 
complex tissue microenvironments.  We show that it is possible to discover genes with differential 
action across tissues, as exemplified by T cell accumulation in tumors compared to secondary lymphoid 
organs.  For genes with tissue-selective action, T cell proliferation and survival are likely to be under the 
control of the T cell receptor and therefore do not occur in tissues lacking presentation of a relevant 
antigen.  Targeting of such genes may offer new approaches to modify the activity of T cells in cancer 
and other pathologies.  For example, recent clinical trials have shown that transfer of genetically 
modified T cells can result in substantial anti-tumor activity30.  The efficacy of such T cell therapies 
could be enhanced by shRNA-mediated targeting of genes that inhibit T cell function in the tumor 
microenvironment.   
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Methods Summary  
In vivo shRNA screening.  Nine shRNA pools (~5 shRNAs per gene) were created and subcloned into 
the pLKO-Thy1.1 lentiviral vector.  Each pool also included 85 negative-control shRNAs.  OT-I T cells 
were cultured with IL-7 (5ng/mL) and IL-15 (100ng/mL); on day 2 cells were spin-infected with 
lentiviral pools supplemented with protamine sulfate (5g/mL) in retronectin-coated 24-well plates 
(5μg/mL) at a multiplicity of infection (MOI) of 15.  Following infection, OT-1 cells were cultured with 
IL-7 (2.5ng/mL), IL-15 (50ng/mL) and IL-2 (2ng/mL).  On day 5, shRNA-transduced T cells were 
enriched by positive selection using the Thy1.1 surface reporter (Stemcell Technologies).  T cells 
(5×106) were injected i.v. into C57BL/6 mice bearing day 14 B16-Ova tumors (15 mice per shRNA 
pool).  Seven days later, shRNA-expressing T cells (CD8+Vα2+Vβ5+Thy1.1+) were isolated by flow 
cytometry from tumors, spleens, tumor-draining lymph nodes and irrelevant lymph nodes.  Genomic 
DNA was purified (Qiagen) and deep-sequencing templates were generated by PCR amplification of the 
shRNA cassette.  Representation of shRNAs in each pool was analyzed by deep sequencing using an 
Illumina Genome Analyzer31.   
Secondary screens were performed using focused pools containing ~15 shRNAs/gene as well as 85 
negative controls.  Cut-off in the secondary screen was defined as >3 shRNAs with >4 fold enrichment 
in tumor relative to spleen.  Screening results were validated at a cellular level by introducing individual 
shRNAs into T cells, along with a reporter protein (GFP, TFP, RFP or Ametrine fluorescent proteins, 
Thy1.1).  This approach enabled simultaneous testing of five shRNAs in an animal (three mice per 
group).  Proliferation of shRNA-transduced T cells was visualized based on CFSE dilution after 24 
hours as well as 3, 5 and 7 days.  
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Figure legends 
Figure 1  In vivo RNAi discovery of immunotherapy targets.  a, Approach for in vivo discovery of 
shRNAs that enhance T cell function in tumors.  OT-I CD8 T cells cultured in IL-7/IL-15 were 
transduced with shRNA pools and injected into mice bearing day 14 B16-Ova tumors.  Seven days later, 
OT-I T cells were isolated from tumors and lymphoid organs.  The shRNA cassette was amplified by 
PCR using genomic DNA from purified T cells.  Representation of all hairpins was quantified in 
different organs by deep sequencing.  b, Summary of shRNA screens for kinases/phosphatases and 
genes upregulated in dysfunctional T cells.  Positive genes in secondary screen were defined as >3 
shRNAs with >4-fold enrichment in tumors relative to spleen.  c, Deep sequencing data from in vivo 
shRNA pool screen.  Upper row, sequence reads for all genes in a pool in tumor, irrelevant (irLN) and 
draining lymph node (dLN); lower row, three individual genes (LacZ, negative control).  Sequence reads 
are plotted for these tissues versus spleen.  Dashed lines indicate a deviation by log2 from diagonal.  d, 
Functional classification of candidate genes from secondary screen. 
 
Figure 2  shRNA-driven accumulation of CD4 and CD8 T cells in B16 melanoma.  a, Flow 
cytometry-based quantification of CD8 T cell enrichment in tumors.  OT-I T cells transduced with 
lentiviral shRNA vectors were injected into mice bearing day 14 B16-Ova tumors.  Seven days later, 
percentage of shRNA-expressing T cells was determined by flow cytometry in tumors/spleens by gating 
on reporter proteins in CD8+V2+V5+ T cells.  Statistical significance was determined for each 
experimental shRNA against LacZ shRNA (fold enrichment tumor/spleen) (n=3).  b, CD8+ OT-I or 
CD4+ TRP-1 T cells expressing Ppp2r2d or LacZ shRNAs were injected into mice bearing day 14 B16-
17 
 
Ova tumors.  Thy1.1 reporter was used to identify shRNA-expressing T cells in tumors and spleens (% 
Thy1.1+ CD8 T cells, left panels).  Total numbers of LacZ or Ppp2r2d shRNA-expressing T cells were 
determined in tumors and spleens 7 days following transfer of 2x106 shRNA-expressing cells (right 
panels).  Fold-enrichment of Ppp2r2d versus LacZ shRNA-expressing T cells in tumors is indicated 
(n=4).  c, Reversal of Ppp2r2d shRNA-mediated T cell expansion in tumors by Ppp2r2d cDNA with 
wild-type protein sequence but mutated shRNA binding site.  OT-I T cells transduced with lentiviral 
vectors driving expression of LacZ shRNA, Ppp2r2d shRNA, or Ppp2r2d shRNA + Ppp2r2d mutant 
cDNA were co-injected into B16-Ova bearing mice (n=4).  The three cell populations were identified 
based on co-expressed reporters; fold-enrichment was calculated based on percentage of reporter-
positive cells in tumors versus spleens. d, qPCR quantification of Ppp2r2d mRNA levels in OT-I T cells 
(not expressing a shRNA) 7 days after transfer into B16-Ova tumor-bearing mice (representative data 
from two independent experiments).  Statistical significance was determined using Student’s t-test, * 
p<0.05, ** p<0.01; error bars denote standard deviation.   
 
Figure 3  Changes in T cell function induced by Ppp2r2d shRNA. a, T cell infiltration into tumors.  
OT-I T cells expressing Ppp2r2d or LacZ shRNAs were labeled with CFSE and injected into B16-Ova 
tumor-bearing mice.  Twenty-four hours later transduced T cells were isolated from tumors and spleens 
and quantified by flow cytometry gating on CD8+ T cells.  b, Ppp2r2d shRNA increases T cell 
proliferation in tumors.  Design described in (a) was used to assess T cell proliferation on days 1, 3, 5 
and 7 based on CFSE dilution.  c, Ppp2r2d-silencing inhibits T cell apoptosis in tumors.  OT-I cells 
expressing Ppp2r2d or LacZ shRNAs were injected into B16-Ova tumor-bearing mice. Seven days later, 
transduced T cells were harvested and apoptotic cells were identified by flow cytometry following 
labeling with an antibody specific for activated caspase-3.  d, Increased IFN- secretion by Ppp2r2d-
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silenced T cells.  OT-I T cells isolated from B16-Ova tumor-bearing mice were assayed for IFN- 
expression by intracellular staining.  e, Ppp2r2d-silenced T cells expand in tumors even without 
presentation of tumor antigens by professional antigen presenting cells.  LacZ or Ppp2r2d shRNA-
expressing OT-I T cells were transferred into day 14 B16-Ova tumor-bearing C57BL/6 or b2m-/- mice.  
shRNA-expressing T cells were identified based on expression of teal fluorescent protein (TFP) or 
Thy1.1 (fold enrichment in tumors compared to spleens).  For all experiments data representative of two 
independent trials (n=3; ** p<0.01, Student’s t-test); error bars denote standard deviation. 
 
Figure 4  Silencing of Ppp2r2d enhances anti-tumor activity of CD4 and CD8 T cells.  T cells 
were activated with anti-CD3/CD28 beads, infected with lentiviruses driving LacZ or Ppp2r2d shRNA 
expression and injected into B16-Ova (a,b) or B16 (c) tumor-bearing mice.  Tumor size was measured 
every three days following T cell transfer using calipers on the two longest axes.   a,b CD4+ TRP-1 
and/or CD8+ OT-I T cells (2 x 106) were transferred (day 12 and 17) into mice bearing day 12 B16-Ova 
tumors.  Tumor burden (a) and survival (b) were assessed.  c, CD4+ TRP-1 and CD8+ pmel-1 T cells 
(3x106 CD4+ TRP-1 plus 3x106 CD8+ pmel-1) were transferred (day 10 and 15) into mice with day 10 
B16 tumors.  Log-rank (Mantel-Cox) test was performed using GraphPad Prism version 6 comparing 
survival of mice treated with LacZ versus Ppp2r2d shRNA-expressing T cells.  Error bars denote 
standard error of the mean.  Data representative of two independent experiments (n=7-9 mice/group). 
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Methods  
 
In vivo shRNA screening.  shRNAs targeting 255 genes over-expressed in dysfunctional T cells 
(anergic or exhausted state)32-38 and 1,307 kinase/phosphatase genes (~5 shRNAs per gene) were 
obtained from The RNAi Consortium (TRC; Broad Institute, Cambridge, MA, USA).  Nine pools were 
created and shRNAs subcloned into the pLKO-Thy1.1 lentiviral vector.  Each pool also contained 85 
negative-control shRNAs (number of shRNAs: GFP, 24; LacZ, 20; luciferase 25; RFP 16).  OT-I T cells 
isolated by negative selection (Stemcell Technologies) were cultured with IL-7 (5ng/mL, Peprotech) and 
IL-15 (100ng/mL, Peprotech) in complete RPMI media (RPMI 1640, 10% FBS, 20mM HEPES, 1mM 
sodium pyruvate, 0.05mM 2-mercaptoethanol, 2mM L-glutamine,  100g/ml streptomycin and 
100g/ml penicillin).  On day 2, OT-I T cells (2x106/well) were spin-infected with lentiviral pools 
supplemented with protamine sulfate (5 g/mL) in 24-well plates coated with retronectin (5μg/mL) at a 
multiplicity of infection (MOI) of 15. Typically ~50x106 OT-1 T cells were infected for each pool. 
Following infection, OT-I cells were cultured with IL-7 (2.5ng/mL), IL-15 (50ng/mL) and IL-2 
(2ng/mL, BioLegend) in complete RPMI media.  On day 5, live cells were enriched using a dead cell 
removal kit (Miltenyi), and infected cells (20-25% Thy1.1+) were positively selected based on Thy1.1 
marker (Stemcell Technologies) to 50-60% Thy1.1 positivity.  T cells (5×106) were injected i.v. into 
C57BL/6 mice bearing day 14 B16-Ova tumors (2x105 tumor cells injected on day 0), 15 mice per 
shRNA pool.  Genomic DNA was isolated from 5×106 enriched OT-I cells as the start population for 
deep sequencing.  Seven days later, shRNA-expressing T cells (CD8+Vα2+Vβ5+Thy1.1+) were isolated 
by flow cytometry from tumors, spleens, tumor-draining lymph nodes and irrelevant lymph nodes.  
Genomic DNA was isolated (Qiagen) and deep-sequencing templates were generated by PCR of the 
shRNA cassette.  Representation of shRNAs in each pool was analyzed by deep sequencing using an 
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Illumina Genome Analyzer31.  Data were normalized using the average reads of control shRNAs in each 
pool.  Kinase/phosphatase genes were selected for the secondary screen based on expression levels in T 
cells (Immunological Genome Project, http://www.immgen.org/).  For the secondary screen, ~10 
additional shRNAs were synthesized for each gene (IDT) for a total of ~15 shRNAs per gene.  These 
focused pools contained 85 negative-control shRNAs.  Two control shRNAs (one for RFP, one for 
luciferase) showed some enrichment in tumors relative to spleen (4.0 and 5.1-fold, respectively).  Cut-
off in the secondary screen was defined as >3 shRNA, with >4 fold enrichment in tumors relative to 
spleen.  
T cell isolation from tumors. B16-Ova melanomas were cut into small pieces in petri dishes containing 
5mL of PBS, 2% FBS and washed with PBS.  Tumors were resuspended in 15 mL RPMI supplemented 
with 2% FBS, 50U/mL Collagenase Type IV (Invitrogen), 20U/mL DNase (Roche), samples incubated 
at 37º C for 2 hours and tissue further dissociated using a gentleMACS Dissociator (Miltenyi Biotech).  
Suspensions were washed three times with PBS and passed through a 70 μM strainer.  Lymphocytes 
were isolated by density gradient centrifugation and then either analyzed or sorted by flow cytometry 
using a FACSAria (BD Biosciences).   
Quantification of T cell enrichment in tumors by flow cytometry. Individual shRNAs were cloned 
into lentiviral vectors encoding five different reporter proteins (GFP, TFP, RFP or Ametrine fluorescent 
proteins, Thy1.1).  Cytokine-pretreated OT-I T cells were transduced with lentiviral vectors driving 
expression of a single shRNA/reporter; 1×106 T cells of each population were mixed and co-injected i.v. 
into C57BL/6 mice bearing day 14 B16-Ova tumors.  Seven days later, T cell populations were 
identified by flow cytometry based on co-introduced reporters.  Fold-enrichment in tumors compared to 
spleen was calculated based on the percentage of OT-I T cells in each organ expressing a particular 
reporter.  In other experiments, 2×106 OT-I CD8 or TRP-1 CD4 T cells were transduced with lentiviral 
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vectors encoding Ppp2r2d or LacZ shRNAs (Thy1.1 reporter) and injected into mice bearing day 14 
B16-Ova (for OT-I T cells) or B16 (for TRP-1 T cells) tumors.  On day 7, absolute numbers of shRNA-
expressing T cells were determined in tumors and spleens.   
T cell migration, proliferation and cytokine secretion. OT-I T cells expressing LacZ or Ppp2r2d 
shRNAs were purified using the Thy1.1 reporter and cultured in complete RPMI media without added 
cytokines for 24 hours.  Live cells isolated by Ficoll density gradient centrifugation (Sigma) were 
labeled with CFSE (carboxyfluorescein diacetate, succinimidyl ester, Invitrogen), and 2×106 labeled 
cells were injected into mice bearing day 14 B16-Ova tumors.  CFSE dilution was quantified by flow 
cytometry at 24 hours and days 3, 5 and 7 following transfer.  In addition, intracellular staining was 
performed on days 3, 5 and 7 for IFN, TNFα and isotype controls (BD).  
T cell apoptosis. Cytokine pre-treated OT-I cells were transduced with LacZ or Ppp2r2d shRNAs and 
injected into mice bearing day 14 B16-Ova tumors. After 7 days, intracellular staining was performed 
using an activated caspase-3 antibody (Cell Signaling) and CD8/Thy1.1 double-positive T cells were 
gated in the FACS analysis. 
Treatment of tumors by adoptive T cell transfer.  B16-Ova cells (2×105 ) were injected s.c. into  
female C57BL/6 mice (10 weeks of age).  On day 12, mice bearing tumors of similar size were 
randomized into 7 groups (7-9 mice/group; sample size based on therapeutic activity of ppp2r2d OT-1 T 
cells in small pilot experiments). Anti-CD3/CD28 bead activated CD4 TRP-1 or/and CD8 OT-I T cells 
infected with Ppp2r2d or LacZ shRNA vectors  (2x106 T cells each) were injected i.v. on days 12 and 
day 17.  For the treatment of B16 tumors, mice were treated at day 10 with anti-CD3/CD28 bead 
activated CD4 TRP-1 and CD8 pmel-1 T cells expressing Ppp2r2d or LacZ shRNAs (3x106 T cells 
each).  Tumor size was measured every three days following transfer and calculated as length × width 
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(investigator performing measurements was blinded to treatment group).  Mice with tumors ≥20 mm on 
the longest axis were sacrificed. 
 
32. Wherry, E.J., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. 
Immunity 27, 670-684 (2007). 
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(2002). 
35. Zha, Y., et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat 
Immunol 7, 1166-1173 (2006). 
36. Lopes, A.R., et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control 
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37. Kurella, S., et al. Transcriptional modulation of TCR, Notch and Wnt signaling pathways in SEB-
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38. Xu, T., et al. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in 
melanoma patients and healthy donors. Cancer research 64, 3661-3667 (2004). 
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Supplementary Figure 1  In vivo RNAi screening procedure. a, Infection of CD8+ T cells from 
Rag1-/-/OT-I TCR transgenic mice with shRNA pools.  T cells were either activated with anti-
CD3/CD28 beads or exposed to recombinant murine IL-7/IL-15 for 48 hours.  T cells were then infected 
with a LacZ control shRNA lentiviral vector and cultured for an additional three days.  Transduction 
efficiency was determined based on expression of the Thy1.1 reporter encoded by the lentiviral vector.  
Cytokine-cultured T cells expressing the LacZ control shRNA were then stained with a panel of 
activation markers (blue lines; isotype control, shaded).  The majority of infected T cells exhibited a 
central memory phenotype (CD62L+CD44+).  b, Representative flow cytometry plots of OT-I T cells 
sorted from tumors and secondary lymphoid organs for deep sequencing analysis (dLN, tumor-draining 
lymph node; irLN, irrelevant lymph node).  CD8+V2+V5+Thy1.1+ cells were sorted and genomic 
DNA was extracted for PCR amplification of the shRNA cassette. c, Deep sequencing results from T 
cell dysfunction screen.  shRNA sequencing reads for genes positive in secondary screen are plotted in 
comparison to spleen for tumors (red), irrelevant lymph nodes (irLN, blue) and tumor-draining lymph 
nodes (dLN, green), with dashed lines indicating a deviation of log2 from the diagonal.  Data show 
enrichment of particular shRNAs representing these genes in tumors compared to spleens or lymph 
nodes.  d, Deep sequencing results from kinase and phosphatase screen, as described in (c). 
 
Supplementary Figure 2  Tumor-enriched shRNAs from secondary screen. Secondary screens 
were performed with a total of ~15 shRNAs for each gene of interest. a, Results from secondary screen 
of T cell dysfunction pool shRNA library.  Genes for which at least 3 shRNAs showed >4 fold 
enrichment in tumors are listed, along with a brief description of their function.  b, Results from 
secondary screen of kinase and phosphatase shRNA libraries. 
24 
 
Supplementary Figure 3  Validation of shRNAs from in vivo RNAi screen. a, FACS-based 
analysis of T cell enrichment in tumors.  Positive shRNAs from deep sequencing analysis were cloned 
into vectors driving expression of one of four distinct fluorescent proteins (TFP, GFP, RFP, Ametrine) 
or Thy1.1.  OT-I T cells were transduced with shRNA vectors and the five populations of T cells 
(normalized for transduction efficiency) were co-injected into B16-Ova tumor-bearing mice.  T cells 
were isolated from tumors and spleens on day 7, and the percentage of reporter-positive CD8+V2+V5+ 
T cells was determined by flow cytometry.  b, FACS analysis of T cell enrichment in tumors compared 
to spleen (as described above) for  cells expressing a panel of Ppp2r2d or Cblb shRNAs (upper panels).  
Ppp2r2d and Cblb mRNA levels were measured by qPCR prior to T cell transfer (lower panels).  The 
strongest T cell enrichment in tumors was observed for shRNAs with >80% knock-down efficiency at 
the mRNA level (shRNAs #1 and 2 for both Ppp2r2d and Cblb). c, Quantification of Ppp2r2d protein by 
tandem mass spectrometry. Cytokine pre-treated OT-I cells were transduced with LacZ or Ppp2r2d 
shRNAs and sorted to purity using the Thy1.1 marker gene.  Isotopically labeled peptides (referred to as 
AQUA peptides) specific for Ppp2r2d and Actin B were synthesized for quantification.  Cell lysates 
were separated by SDS-PAGE and tryptic peptides eluted from gel slices.  AQUA peptides (300 fmol) 
were added to samples to enable quantification by LC-MS/MS.  AQUA peptides co-eluted with 
endogenous Ppp2r2d and Actin B peptides from the LC column, yet had a 10 Da higher molecular 
weight than the endogenous peptides.  Data are represented as the ratio of endogenous (end) to AQUA 
peptides for both Actin B and Ppp2r2d in T cells expressing Ppp2r2d or LacZ shRNAs.  Statistical 
significance was examined with Graphpad 6.0 software using the Student t-test (* p = 0.0062). 
 
Supplementary Figure 4  Specificity of Ppp2r2d shRNA. a, Generation of mutant Ppp2r2d cDNA 
with wild-type protein sequence but disrupted shRNA binding site.  Both mutant and wild-type Ppp2r2d 
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cDNAs were cloned into a modified pLKO.3G vector with a 2A peptide ribosomal skip sequence and 
GFP.  This approach resulted in stoichiometric expression of Ppp2r2d protein and GFP in EL4 thymoma 
cells.  GFP-expressing EL4 cells were sorted to purity and transduced with LacZ or Ppp2r2d shRNA 
vectors expressing a Thy1.1 reporter.  shRNA-transduced (Thy1.1+) cells were analyzed by flow 
cytometry for GFP expression.  The Ppp2r2d shRNA reduced GFP levels when wild-type Ppp2r2d 
cDNA, but not when mutant Ppp2r2d cDNA was co-expressed.  b, Expression of Ppp2r2d mutant cDNA 
prevents phenotype induced by Ppp2r2d shRNA.  OT-I T cells were transduced with a vector encoding 
LacZ shRNA, Ppp2r2d shRNA or Ppp2r2d shRNA plus mutant Ppp2r2d cDNA. The different cell 
populations were normalized for transduction efficiency and co-injected into B16-Ova tumor bearing 
mice.  The percentage of each T cell population in tumors and spleens was quantified by gating on 
CD8+V2+V5+ T cells; transduced cells were detected based on expression of Thy1.1 or Ametrine/GFP 
fluorescent reporters (representative data from 2 independent experiments, n=3 mice per experiment).  c, 
Real-time PCR analysis for Ppp2r2d expression in OT-I T cells transduced with LacZ shRNA, Ppp2r2d 
shRNA, and Ppp2r2d shRNA plus Ppp2r2d mutant cDNA. 
 
Supplementary Figure 5   Expression profiles of gene-silenced CD8 T cells in tumors.  OT-I T 
cells were transduced with lentiviral vectors driving expression of one of five experimental shRNAs or 
LacZ control shRNA. T cells were injected into day 14 B16-Ova tumor-bearing mice and isolated from 
tumors and spleens 7 days later.  Cells were sorted to high purity and total RNA was obtained for 
Affymetrix gene expression profiling.  For each shRNA arrays were performed in triplicate (6 mice per 
group).  a, Two genes (Egr2 and Ptpn2) have known functions in T cells.  Enrichment in tumor versus 
spleen was calculated based on deep sequencing results from the secondary screen.  b, Clustering of 
mean expression levels for mRNAs found to be significantly regulated by T cells in spleens or tumors 
26 
 
expressing the LacZ control shRNA or one of five experimental shRNAs.  Significant expression 
differences were defined as an Anova p value <0.01 between T cells expressing LacZ control shRNA or 
one of five experimental shRNAs (Alk, Arhgap5, Egr2, Ptpn2 or Ppp2r2d) (JMP-Genomics 6.0, SAS 
Institute Inc.). mRNAs significantly regulated in one or more treatment groups are shown after 
clustering (Fast Ward).  c, Venn diagram showing overlaps between expression signatures by tumor-
infiltrating T cells transduced with one of the five experimental shRNAs (signatures defined as an 
Anova p<0.01 as described above).  Indicated are the numbers of overlapping probe IDs for any 
combination of the 5 signatures, as indicated by the overlapping ovals.  The significance of the overlaps 
versus that expected by random chance (Fishers Exact Test) is shown in the accompanying table. 
 
Supplementary Figure 6  Ppp2r2d shRNA enhances T cell proliferation and reduces apoptosis.  
a,  Proliferation of Ppp2r2d shRNA-expressing T cells in tumors and tumor-draining lymph nodes.  OT-
I T cells expressing Ppp2r2d or LacZ shRNAs were labeled with CFSE and injected into B16-Ova 
tumor-bearing mice.  T cells were isolated from the indicated organs on days 1, 3, 5 and 7 to examine 
the extent of T cell proliferation based on dilution of the CSFE dye.  T cells that had not diluted CFSE 
(non-dividing cells) were quantified (right).  b, Viability of tumor-infiltrating T cells. OT-I T cells 
expressing Pp2r2d or LacZ shRNAs were injected into B16-Ova tumor-bearing mice.  T cells were 
isolated on day 7 and apoptosis was assessed by intracellular staining with an antibody specific for 
activated caspase-3. c, OT-I T cells expressing LacZ or Ppp2r2d shRNAs were labeled with CFSE and 
stimulated with B16-Ova tumor cells for 72 h.  Cells were then stained with anti-CD8 and annexin V 
and analyzed by flow cytometry. Data for all experiments are representative of two independent trials 
(n=3; * p<0.05, ** p<0.01, Student’s t-test).  Error bars denote standard deviation.    
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Supplementary Figure 7  Cytokine secretion by gene-silenced tumor-infiltrating T cells. a, 
Intracellular cytokine staining for IFN by LacZ and Ppp2r2d shRNA-expressing T cells harvested from 
B16-Ova tumors (primary flow cytometry analysis for data summarized in Figure 3d). b-d, Ex vivo 
analysis of cytokine production by tumor-infiltrating T cells at a single-cell level using a nanowell 
device.  LacZ or Ppp2r2d shRNA-expressing OT-I cells were injected into mice bearing day 14 B16-
Ova tumors. After 7 days, GFP+ (shRNA-expressing) OT-I T cells were sorted from tumors by FACS 
and deposited into a nanowell device modified with supported lipid bilayers presenting anti-CD3/CD28. 
The device contained a total of 84,672 wells of picoliter volume.  T cells were activated for 3h 
(CD3/CD28 antibodies on bilayers), followed by placement of a slide with immobilized cytokine 
capture antibodies on the device (microengraving) for a 1h period (total stimulation time of 4h).  Slides 
were then removed and stained with secondary fluorophore-conjugated cytokine antibodies prior to 
analysis in a microarray reader.  b, Representative examples of single cells in nanowells and 
corresponding patterns of cytokine secretion revealed by microengraving.  Cells in nanowells were 
labeled with SYTOX green (dead cell marker) and a plasma membrane dye to identify live cells.    c, 
Bar graph showing percentage of LacZ or Ppp2r2d shRNA-expressing OT-I T cells secreting the 
indicated cytokines and cytokine combinations. d, Cytokine secretion rates.  Data from standard 
calibration curves were used to calculate secretion rates for each cell.  The horizontal black lines 
represent the mean and standard deviation.  Statistical significance was tested using the Mann Whitney 
test (* p<0.05). 
 
Supplementary Figure 8  Phenotypic characterization using memory, activation and exhaustion 
markers. a, The majority of adoptively transferred OT-I cells have a memory phenotype in lymph 
nodes but an effector phenotype in tumors. Cytokine pre-treated cells were transduced with Ppp2r2d or 
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LacZ shRNAs and injected into mice bearing 14 day B16-Ova tumors.  On day 7, T cells were harvested 
from the indicated organs and stained with CD62L and CD44 antibodies.  FACS analysis of shRNA-
expressing OT-I cells was performed by gating on CD8/Thy1.1 double-positive cells. b, Analysis of 
exhaustion markers. OT-I cells were harvested from draining lymph nodes and tumors of mice and 
stained with a antibodies specific for TIM-3, LAG-3, PD-1 and CD25.  c, Intracellular staining for 
granzyme B by OT-I T cells in tumor-draining lymph nodes and tumors.  For all experiments (n=3; * 
p<0.05, ** p<0.01, Student’s t-test); error bars denote standard deviation. 
 
Supplementary Figure 9  Histological characterization of anti-tumor response. a, Infiltration of 
shRNA-expressing T cells into tumors. OT-I T cells were transduced with LacZ or Ppp2r2d shRNA 
vectors encoding a GFP reporter and injected into B16-Ova tumor-bearing mice. After 7 days, tumors 
were carefully excised and frozen sections stained with anti-GFP and DAPI to enumerate shRNA-
expressing OT-I T cells in tumors.  b, Tumor cell apoptosis. TUNEL immunohistochemistry was 
performed on tissue sections and apoptotic cells were quantified.  c, MHC class I expression by tumor 
cells.  Tumors were excised from treated mice, digested with collagenase and stained with CD45.2 and 
H-2Kb antibodies. FACS analysis for H-2Kb was performed by gating on CD45.2-negative cells.  
  
Supplementary Table 1. Results from primary and secondary screens.  The Excel file lists gene 
name, gene ID, shRNA clone ID, targeting sequence and enrichment of shRNAs in tumors relative to 
spleen.  The first tab shows results from primary screens, the second tab data from secondary screens. 
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Supplemental methods 
 
Experimental animals. C57BL/6 mice, TRP-1 mice (transgenic mice expressing T-cell receptor (TCR) 
specific for tyrosinase-related protein 1)22, pmel-1 mice (transgenic mice expressing TCR specific for 
gp100)17, and b2m-/- mice23 were purchased from The Jackson Laboratory.  The Rag1-/- OT-I mice15 
were purchased from Taconic Farms, Inc. Female mice aged 7-10 weeks were used for experiments.  
Mice were bred at the Dana-Farber Cancer Institute animal facility.  All experimental procedures were 
approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. 
 
Cell lines. EL4 thymoma39 and B16-F10 melanoma14 cells were purchased from ATCC and maintained 
in RPMI 1640 supplemented with 10% FBS, 2mM  L-glutamine, 100g/ml streptomycin and 100g/ml 
penicillin. Ovalbumin-expressing B16 tumor cells (B16-Ova) were maintained in the same media with 
addition of 600g/mL G418 (Invitrogen). 
 
Vectors and shRNA sequences. pLKO.3G vector was obtained from The RNAi Consortium.  pLKO-
Thy1.1, pLKO-Ametrine, pLKO-RFP, pLKO-TFP vectors were modified from pLKO.3G vector by 
replacing GFP with the corresponding reporter gene.  The 10 shRNA sequences for Ppp2r2d and Cblb 
are listed below in order of activity (highest to lowest, Fig. S3). The LacZ control shRNA sequence is 
also listed. All other shRNA sequences can be found in Supplementary Table 1. 
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# Gene Clone ID Sequence 
LacZ TRCN0000072227 GCGCTAATCACGACGCGCTGT 
1 Ppp2r2d TRCN0000080900 CCCACATCAGTGCAATGTATT 
2 Ppp2r2d ND000492 CCACAGTGGTCGATACATGAT 
3 Ppp2r2d TRCN0000431278 GAGAATTAACCTATGGCATTT 
4 Ppp2r2d ND000486 GCTCAATAAAGGCCATTACTC 
5 Ppp2r2d TRCN0000080901 CCATTTAGAATTACGGCACTA 
6 Ppp2r2d TRCN0000430828 ATAGTGATCATGAAACATATC 
7 Ppp2r2d TRCN0000080899 GCCACCAATAACTTGTATATA 
8 Ppp2r2d TRCN0000080902 CGGTTCAGACAGTGCCATTAT 
9 Ppp2r2d TRCN0000427220 TCATCTCCACCGTTGAGTTTA 
10 Ppp2r2d TRCN0000425449 ATGCTCATACATATCACATAA 
1 Cblb ND000025 CGAGCGATCCGGCTCTTTAAA 
2 Cblb ND000030 AGCCAGGTCCAATTCCATTTC 
3 Cblb TRCN0000244606 CCCTGATTTAACCGGATTATG 
4 Cblb ND000026 ATCGAACATCCCAGATTTAGG 
5 Cblb TRCN0000244603 CTACACCTCACGATCATATAA 
6 Cblb ND000024 TACACCTCACGATCATATAAA 
7 Cblb TRCN0000244605 TGAGCGAGAATGAGTACTTTA 
8 Cblb TRCN0000244604 CCAGATTTAGGCATCTATTTG 
9 Cblb TRCN0000244607 CTTGTACTCCAGTACCATAAT 
10 Cblb ND000027 TCTACATCGATAGTCTCATGA 
 
Antibodies and flow cytometry. Single-cell suspensions were stained in PBS, 2% FBS with labeled 
antibodies at 4°C for 20 minutes, followed by two washes with ice-cold PBS, 2% FBS.  Cells were 
analyzed/sorted using a FACSAria (BD Biosciences) and FlowJo software (TriStar).  Antibodies used 
were specific for CD4, CD8, Vα2, Vβ5.1/5.2, Thy1.1, CD25, CD44, CD62L, CD69, CD122, CD127, 
IFN, TNFα, PD-1, TIM-3, LAG-3, granzyme B, and H-2Kb (BioLegend), Vα3.2 (eBioscience), Vβ13, 
Vβ14 (BD Biosciences).  Apoptotic cells were detected by labeling with annexin V (BioLegend) or 
activated caspase-3 antibody (Cell Signaling).  Mouse anti-CD3/CD28 beads were purchased from 
Invitrogen.  
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Immunofluorescence and immunohistochemistry. B16-Ova tumors from mice treated with OT-I T 
cells expressing LacZ or Ppp2r2d shRNAs (GFP-expressing vector) were cryopreserved in optimal 
cutting temperature (O.C.T.) compound (Tissue-Tek). 10 μm-sections from cryopreserved tumors were 
were permeabilized with 0.2% Triton X-100, fixed in 4% paraformaldehyde and stained with a GFP 
antibody (Molecular Probes) in combination with DAPI.  For TUNEL detection, sections were stained 
with TACS 2 TdT Blue Label (Trevigen) based on manufacturer’s directions.  Samples were visualized 
using a laser-scanning confocal microscope (Leica SP5X) and analyzed with ImageJ software (NIH). 
 
qRT-PCR assay. Total RNA was extracted using TRIzol reagent (Invitrogen).  RNA was reverse 
transcribed with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems).  Real time 
quantitative PCR reactions were performed in triplicates using an ABI 7900HT instrument with SYBR 
green (ABI).  Rpl23 levels were used for normalization.  The following primers were used: Ppp2r2d 
forward GGAAGCCGACATCATCTCCAC, Ppp2r2d reverse GTGAGCGCGGCCTTTATTCT; Cblb 
forward GGTCGCATTTTGGGGATTATTGA, Cblb reverse TTTGGCACAGTCTTACCACTTT; 
Rpl23 forward CTGTGAAGGGAATCAAGGGA and Rpl23 reverse TGTCGAATTACCACTGCTGG. 
 
Quantification of Ppp2r2d protein levels by mass spectrometry.  A previously reported approach for 
absolute quantification (AQUA) of proteins from cell lysates by mass spectrometry was used to measure 
the effect of Ppp2r2d shRNA expression at the protein level40.  This strategy is based on a ‘selective 
reaction monitoring’ approach in which a synthetic peptide with incorporated stable isotopes is used as 
an internal standard for mass spectrometry analysis.  OT-I cells expressing LacZ or Ppp2r2d shRNAs 
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were sorted to purity using FACS.  Cells (1x106) were lysed in 1ml of MPER extraction reagent (Pierce) 
containing a Protease Inhibitor Cocktail (Sigma), 1mM EDTA and 1mM PMSF for 15 minutes on ice 
with occasional vortexing.  Cell debris was removed by centrifugation and the protein supernatant was 
filtered (0.2μm SpinX centrifuge filter, Costar).  Protein concentration was determined by Bradford 
assay (Biorad) and UV280 nm analysis (Nanodrop instrument); 0.1 mg of cellular proteins were 
separated by SDS-PAGE and stained with Coomassie blue reagent (Pierce).  Gel bands corresponding to 
a MW range of 45-60kDa were excised followed by in-gel digestion of proteins with trypsin.  Eluted 
peptides were  spiked with 300 fmol of isotopically labeled Ppp2r2d (FFEEPEDPSS[13C-15N-R]-OH) 
and Actin B (GYSFTTTAE[13C-15N-R]-OH) peptides (21st Century Biochemicals) for quantification 
by LC-MS/MS (LTQ XL Orbitrap, Thermo Scientific).  The Ppp2r2d peptide was chosen from a region 
of the protein that differs from other regulatory subunits of PP2A.  Initially, a LC-MS/MS run of a LacZ 
shRNA sample was analyzed to localize the Ppp2r2d and Actin B peptides that were being monitored.  
The AQUA peptides co-eluted with the corresponding endogenous peptides from the reverse-phase 
column, yet their higher MW (10 Da) enabled the ratio of peak intensity of endogenous and AQUA 
peptides to be determined using abundant peptide fragment ions.  Triplicate samples were analyzed by 
SDS-PAGE - LC-MS/MS and statistical significance was determined using Graphpad Prism 6.0 
software using a Student t-test (F test, * p=0.0062).   
 
Microarray analysis.  IL-7/IL-15 cultured OT-I T cells were transduced with one of five experimental 
shRNAs (Ppp2r2d, Arhgap5, Alk, Egr2, Ptpn2) or a LacZ control shRNA.  Infected cells were sorted to 
purity using GFP encoded by the vector as a reporter.  T cells (5×106) were injected i.v. into mice 
bearing day 14 B16-Ova tumors.  Seven days later, shRNA-expressing OT-I T cells (CD8+GFP+) were 
isolated from tumors and spleens.  Cells were sorted twice to high purity and total RNA was extracted 
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using TRIzol reagent (Invitrogen) for Affymetrix gene expression profiling (Mouse Genome 430 2.0 
Arrays).  Arrays for each shRNA were done in triplicate (6 mice per group).   
 
Testing of on-target activity of Ppp2r2d shRNA.  Wild-type Ppp2r2d cDNA was isolated by RT-PCR 
using forward primer 5’ GGATCCATGGCAGGAGCTGGAGGC 3’ and reverse primer: 5’ 
GCTAGCATTAATTTTGTCCTGGAATATATACAAGTTATTGGTGG 3’.  In this cDNA the target 
sequence of Ppp2r2d shRNA, CCCACATCAGTGCAATGTATT was mutated to 
TCCCCACCAATGTAACGTGTT by overlapping PCR (which conserves protein coding sequence) 
using forward primer: 5’ TCCATCCCCACCAATGTAACGTGTTTGTTTACAGCAGCAGCAAGG 3’ 
and reverse primer: 5’ AAACAAACACGTTACATTGGTGGGGATGGAACTCTGCGGCAGTGA 3’. 
Both wild-type and mutant Ppp2r2d cDNAs were cloned into a modified pLKO.3 vector with a 2A 
ribosomal skip peptide-GFP sequence (resulting in stoichiometric Ppp2r2d and GFP expression in cells).  
Constructs were introduced into EL4 thymoma cells.  GFP-expressing EL4 cells were sorted to purity 
and then transduced with LacZ or Ppp2r2d shRNA lentiviral vectors driving expression of a Thy1.1 
reporter.  shRNA-transduced (Thy1.1+) cells were analyzed by flow cytometry for GFP expression.  The 
Ppp2r2d shRNA was not able to reduce expression of the GFP reporter in cells expressing the mutant 
Ppp2r2d cDNA, demonstrating that the shRNA binding site had been successfully mutated.   
Ppp2r2d shRNA was subsequently cloned into the mutant Ppp2r2d cDNA-2A-GFP construct which 
resulted in co-expression of Ppp2r2d shRNA and mutated Ppp2r2d cDNA in one vector.  OT-I T cells 
were separately infected with lentiviruses encoding LacZ shRNA (Thy1.1), Ppp2r2d shRNA (Ametrine) 
or Ppp2r2d shRNA plus mutant Ppp2r2d cDNA (GFP).  These three populations were then mixed at the 
same ratio and co-injected into mice bearing day 14 B16-Ova tumors.  On day 7, each T cell population 
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was quantified in tumors and spleens by gating on OT-I (Vα2+Vβ5+) T cells followed by analysis of 
populations marked by Thy1.1, Ametrine or GFP expression.  
 
Nanowell analysis of cytokine production at a single cell level 
Materials.  Antibodies used for T cell activation were anti-mouse CD3 (clone 145-2C11) and anti-
mouse CD28 (clone 37.51) (Biolegend).  Antibodies used to capture secreted cytokines were anti-mouse 
IFN (clone R4-6A2, Biolegend), anti-mouse IL-2 (clone JES6-1A12, Biolegend), anti-mouse TNF 
(clone  6B8, Biolegend) and anti-mouse GM-CSF (clone  MP1-22E9, Biolegend).  Detection antibodies 
were anti-mouse IFN (clone XMG1.2, Biolegend), anti-mouse IL-2 (clone JES6-5H4, Biolegend), anti-
mouse TNF (clone MP6-XT22, Biolegend) and anti-mouse GM-CSF (clone MP1-31G6, Biolegend), 
and they were fluorescently labeled with appropriate Alexa Fluor dyes (Invitrogen) following 
manufacturer’s instructions.  The lipids used to prepare supported bilayers were: 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap 
biotinyl) (Biotinyl Cap PE ) (Avanti Polar Lipids).   
 
Fabrication of PDMS arrays of nanowells and preparation of supported lipid bilayers.  The array 
of nanowells was manufactured by injecting polydimethylsiloxane (PDMS, Dow Corning) prepared at a 
10:1 base/catalyst weight ratio into a custom-built mold encasing a micropatterned silicon master.  
Arrays of nanowells were cured at 70 °C for 4-16 h.  Each array comprised 72 x 24 blocks, each 
containing a 7 x 7 (50 μm x 50 μm x 50 μm) subarray of nanowells (total of 84,672 wells).  The PDMS 
arrays adhered directly to a 3 x 1 glass slide forming a 1 mm thick layer.  Supported lipid bilayers 
were prepared as described previously41.  Bilayers were generated by applying DOPC liposomes 
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containing 2 mol% biotin-Cap-PE lipids on the PDMS array of nanowells.  The surfaces were rinsed 
with deionized water to remove excess liposomes.  Before use, the lipid bilayer was blocked with BSA 
in PBS (100 μg/mL) for 45 minutes.  The bilayer was then incubated with 1 μg/mL of streptavidin in a 
solution of 100 μg/mL BSA in PBS, followed by incubation with biotinylated CD3 and CD28 
antibodies.  The device was rinsed extensively with PBS before adding the cells. 
Microengraving.  Capture antibodies were diluted in borate buffer (50 mM sodium borate, 8 mM 
sucrose, and 50 mM NaCl, pH 9.0) to a final concentration of 10 g/mL and deposited on the surface of 
epoxy-modified slides for 1 h at room temperature.  Slides were blocked with 3% non-fat milk in PBST 
(PBS with 0.05% (v/v) Tween 20) for 30 min at room temperature and washed with PBS before placing 
them into contact with the PDMS array of nanowells.  A suspension of T cells was dispensed onto the 
surface of the nanowells, modified with a supported lipid bilayer in media and allowed to settle into the 
wells.  The density of suspended cells applied to the array was optimized empirically to maximize well 
occupancy with single cells (typically ~30% of wells).  After incubation of the cell-loaded wells, a glass 
slide coated with capture antibodies was then placed onto the loaded array for cytokine capture.  The 
microarray and glass slide were held together by compression in a hybridization chamber (Agilent 
Technologies, G2534A) and incubated for 1h at 37 °C with 5% CO2.  The glass slide was then separated 
from the array and placed in PBS.    
After microengraving, slides were incubated for 30 min with blocking buffer (PBS, 10mg/mL BSA, 0.05 
% (v/v) Tween-20, 2% mouse serum and 2 mM sodium azide), washed with PBST (PBS+ 0.05% v/v 
Tween-20), and then incubated with fluorescence detection antibodies at 1 g/mL for 45 min at 25°C.  
The slides were washed with PBST and PBS, rinsed briefly with water, and dried with a N2 stream.  
Reference slides were generated at the end of each experiment with the same detection antibodies used 
on the printed slides.  For reference slides, antibodies were diluted in water, spotted onto blank poly-L-
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lysine slides (1 L/spot), and the reference slides were dried under vacuum.  Slides were scanned using a 
Genepix 4200AL microarray scanner (Molecular Devices).  The median fluorescence intensity of each 
spot was extracted using Genepix Pro.  
On-chip image-based cytometry.  Before imaging, T cells were stained with CellMask™ Plasma 
Membrane Stain (Invitrogen, Life Technologies) and SYTOX green (for detection of dead cells, Life 
Technologies).  The cell-loaded arrays of nanowells were mounted face-up on the microscope with a 
coverslip placed on top of the array.  Images were acquired on an automated inverted epifluorescence 
microscope (Carl Zeiss).  Transmitted light and epifluoresence micrographs were collected block-by-
block (7 x 7 microwells per block).  The resulting collection of images was analyzed using a custom 
program to determine the number of cells present in each well and the mean fluorescent intensity of each 
label.  Only viable T cells were considered for the analysis.  Although the cells expressed GFP, the 
fluorescent intensity of GFP was negligible under the utilized microscope acquisition setting compared 
to SYTOX green, enabling identification of dead cells. 
 
Data analysis.  Data extracted from both on-chip cytometry and printed cytokines were matched in 
Microsoft Excel using unique identifiers assigned to each well within the array.  The dataset was filtered 
to include wells containing only single cells.  To compensate from signal bleed-through and convert the 
measured fluorescence intensity for the captured cytokines from a given cell into a rate of secretion, the 
data from standard calibration curves (from reference slides) prepared with known amounts of detection 
antibodies was used to convert measured intensities to a number of molecules, as described previously 
42. 
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Symbol
Total # 
shRNAs
Enrichment 
(fold) Function
1 Rbks 6 4.0 - 12.8 Ribokinase, carbohydrate metabolism
2 Pkd1 6 4.9 - 9.9 Cell cycle arrest (activates JAK/STAT pathway)
3 Ppp2r2d 5 4.0 - 17.2 Regulatory subunit of PP2A phosphatase
4 Eif2ak3 5 4.8 - 13.4 ER stress sensor, resistance of cancer cells to chemotherapy
5 Ptpn2 5 4.7 - 7.4 Inhibitor of T cell and cytokine signaling
6 Hipk1 4 4.5 - 12.3 Interacts with p53 and c-myb, knockout mice develop fewer carcinogen-induced tumors
7 Grk6 4 4.2 - 11 Regulator of particular G-protein coupled receptors
8 Cdkn2a 4 4.1 - 7.2 G1 cell cycle arrest and apoptosis in T cells
9 Sbf1 4 4.8 - 6.9 Activates MTMR2, which dephosphorylates PI(3)P and PI(3,5)P2
10 Ipmk 4 4.0 - 6.9 Inositol polyphosphate kinase, nuclear functions such as chromatin remodeling
11 Rock1 4 4.1 - 6.5 Rho kinase, inhibitors have shown activity in mouse models of cancer
12 Stk17b 4 4.0 - 6.4 Inhibitor of T cell signaling forms complex with protein kinase D 
13 Mast2 4 4.1 - 5.1 Microtubule-associated serine/threonine kinase 
14 Arhgap5 3 6.0 - 15.7 Negative regulator of Rho GTPases, inhibition can reduce cancer cell invasion
15 Alk 3 9.6 - 13.5 Anaplastic lymphoma kinase (translocation of nucleophosmin and ALK in ALCL)
16 Nuak 3 4.5 - 13.1 Member of AMP-activated protein kinase-related kinase family, oncogene in melanoma
17 Akap8l 3 4.4 - 11.8 A-kinase anchoring protein, recruits cAMP-dependent protein kinase (PKA) to chromatin
18 Pdp1 3 4.1 - 9.8 Pyruvate dehydrogenase phosphatase 1, regulation of glucose metabolism
19 Yes1 3 5.4 - 9.7 Src family kinase, oncogene in several tumors
20 Met 3 4.1 - 8.9 Receptor tyrosine kinase, involved in hepatocellular and other cancers
21 Ppm1g 3 6.2 - 8.2 Dephosphorylates spliceosome substrates and histones H2A-H2B
22 Blvrb 3 5.3 - 8.0 Biliverdin reductase, also transcription factor, arrest of cell cycle
23 Tnk1 3 5.2 - 7.6 Downregulates Ras pathway (phosphorylation of Grb2), inhibition of NF-kB pathway
24 Prkab2 3 4.1 - 7.0 Subunit of AMP kinase, inhibits fatty acid synthesis and mTOR pathway
25 Trpm7 3 4.9 - 5.9 Ion channel and serine-threonine kinase
26 Ppp3cc 3 4.2 - 4.4 Regulatory subunit of calcineurin (phosphatase in T cell receptor signaling)
Symbol
Total # 
shRNAs
Enrichment 
(fold) Function
1 Dgkz 6 5.2 - 14.0 Phosphorylates and thereby inactivates DAG 
2 Egr2 6 4.0 - 10.2 Transcription factor involved in T cell unresponsiveness, expression of Cblb
3 Smad2 5 6.7 - 30.3 TGF beta signaling pathway
4 Cblb 5 4.1 - 10.8 E3 ubiquitin ligase (degradation of TCR and signaling molecules; ko mice reject tumors)
5 Inpp5b 5 4.3 - 9.5 Inositol polyphosphate-5-phosphatase, hydrolyzes PIP2
6 Socs1 5 4.1 - 8.5 Inhibitor of cytokine signaling
7 Jun 5 5.2 - 6.4 Persistent AP-1 activation in tumor-infiltrating T cells leads to upregulated PD-1 
8 Vamp7 4 4.0 - 11.3 Vesicle associated transmembrane protein
9   Dgka 4 5.0 - 10.2 Phosphorylates and thereby inactivates DAG
10 Mdfic 4 4.4 - 10.0 Inhibits viral gene expression, interacts with cyclin T1 and T2 
11 Nptxr 4 4.0 - 7.2 Pentraxin Receptor
12 Socs3 4 4.6 - 6.3 Inhibitor of cytokine signaling
13 Entpd1 3 6.5 - 13.3 Extracellular degradation of ATP to AMP (an inhibitory signal through AMP kinase)
14
F11r 3 4.6 - 6.8
Pdz1ip1 3 4.8 - 12.9 Pdzk1 interacting protein, expression correlates with tumor progression
15 Cell Migration
16 Fyn 3 4.1 - 6.5 Inhibits activation of resting T cells (through Csk)
17 Ypel2 3 4.6 - 5.1 Function unknown
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Gene Symbol Function Enrichment Fold
Ppp2r2d Regulatory subunit of PP2A phosphatase 17.2
Arhgap5 Negative regulator of Rho GTPases 15.7
Alk Anaplastic lymphoma kinase (translocation of nucleophosmin and ALK in ALCL) 13.5
Egr2 Transcription factor involved in T cell unresponsiveness, expression of Cblb 10.2
Ptpn2 Inhibitor of T cell and cytokine signaling 7.4
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